Surgery, Gastroenterology and Oncology

Background: Prostate-specific antigen (PSA) is a test performed to detect prostate cancer. Currently, no rational standard exists for its cut-off point, which results in increased patients due to prostate biopsy complications. Therefore, this study aimed to determine the estimated PSA cut-off point and PSA density (PSAD) in patients with suspected prostate cancer (CaP) in Makassar.

Methods: The study sample was patients with benign prostatic hyperplasia (BPH) and cancer of the prostate (CaP) in Makassar, Indonesia. Statistical tests were performed with the Mann-Whitney U, Chi-Square, Fisher's Exact, and ROC tests (significance p = <0.05) with a retrospective research type.

Results: 470 samples were obtained from BPH (88.3%) and CaP (11.7%) patients ranging from 40 to 80 years old. Patients were found at 60-79 years (70.8%) with LUTS symptoms (66%), hematuria (10.6%), urinary retention (42.1%), and US prostate volume ranging from 30-50ml, examination of rectal toucher (RT) BPH 84.3% and CaP 96.4% for assessment of prostate consistency, PSA BPH (14.82 ng ml) and CaP (48.10 ng ml), PSAD BPH (0.28 ng mL2) and CaP (1.19 ng mL2). These values can predict histopathology results (p<0.05) on US volume, risk factors for type II DM, hypertension (p>0.05) can predict histopathology results.

Conclusion: The average CaP PSA was 48.10 ng ml with 18.62 ng ml cut-off point, and PSAD CaP was 1.99 ng mL2 with 0.53 ng mL2 cut-off point, which was higher than in Chinese and American samples.

Full Text Sources:
Abstract:   
Views: 2339